Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978197 | 0.86 | PTGS2 (0.68) | PTGS2PTGS1KMT2ACFTRGOPC | |
| SCHEMBL27874435 | 0.81 | KMT2A (0.46) | PTGS2PTGS1KMT2ACFTRGOPC | |
| SCHEMBL22492006 | 0.79 | KMT2A (0.40) | PTGS2PTGS1KMT2AALDH1A1HTT | |
| SCHEMBL8384573 | 0.79 | KMT2A (0.40) | PTGS2PTGS1KMT2AALDH1A1HTT | |
| SCHEMBL22679771 | 0.79 | BRD4 (0.46) | PTGS2PTGS1KMT2AALDH1A1HTT | |
| SCHEMBL22492035 | 0.79 | SMN1; SMN2 (0.46) | PTGS2PTGS1KMT2AALDH1A1HTT | |
| SCHEMBL24808048 | 0.79 | PTGS2 (0.49) | PTGS2PTGS1KMT2ACFTRGOPC | |
| SCHEMBL28795587 | 0.79 | PTGS2 (0.44) | PTGS2PTGS1KMT2ACFTRGOPC | |
| SCHEMBL8518215 | 0.78 | PTGS2 (0.59) | PTGS2PTGS1KMT2ACFTRGOPC | |
| SCHEMBL20161054 | 0.77 | KMT2A (0.48) | PTGS2PTGS1KMT2ACFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504706-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-2507215-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067219-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | PTGS2 198/4885PTGS1 61/4885KMT2A 2333/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | PTGS2 269/4885PTGS1 73/4885KMT2A 2276/4885 |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | PTGDR2, PTGDR, TBXA2R | PTGS2 396/4885PTGS1 244/4885KMT2A 1919/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | PTGS2 166/4885PTGS1 50/4885KMT2A 2196/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | PTGS2 166/4885PTGS1 50/4885KMT2A 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.